13F Pro13F Pro

Squadron Capital Management LLC

Institutional InvestorSimilar funds →SEC EDGAR: CIK 2050709
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare100.0%$292.1M

AUM History

13fpro.ai/research/fund/squadron-capital-management-llc-2050709

Conviction and streaks

Stable · top 10 = 73.0%

From the fund's last 12 quarters of 13F filings: positions held longest at size, and names it added to or trimmed several quarters running.

COGT$COGTAccumulating+11% shares · 2 quarters runningKOD$KODAccumulating+71% shares · 2 quarters runningIVA$IVAAccumulating+712% shares · 2 quarters runningIKT$IKTTrimming-29% shares · 2 quarters running

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/squadron-capital-management-llc-2050709

Squadron Capital Management LLC 13F holdings — Q2 2026

$322.2M portfolio (+18.1% QoQ) · 43 holdings · Q2 2026 13F · top 10 are 73% of the stock portfolio

Includes $30.2M of put/call options ($0 puts, $30.2M calls), which 13F rules report at the value of the underlying shares, not the premium at risk. Stocks alone: $292.1M. Weights use the stock portfolio.

All holdings — Squadron Capital Management LLC (Q2 2026)

43 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
ELVN$ELVNEnliven Therapeutics, Inc.$8.1MNew
AVBP$AVBPCALLArriVent BioPharma, Inc.$6.4M+66%
PALI$PALIPALISADE BIO, INC.$6.3M—
BIOA$BIOACALLBioAge Labs, Inc.$6.1MNew
IKT$IKTInhibikase Therapeutics, Inc.$6.1M-14%
ADAG$ADAGAdagene Inc.adr$5.3MNew
FBRX$FBRXForte Biosciences, Inc.$4.8MNew
RZLT$RZLTCALLRezolute, Inc.$4.7MNew
IFRX$IFRXInflaRx N.V.$4.5MNew
ASMB$ASMBASSEMBLY BIOSCIENCES, INC.$4.4MNew
CMPS$CMPSCALLCOMPASS Pathways plc$4.3MNew
PMN$PMNProMIS Neurosciences Inc.$4.3M—
CTNM$CTNMContineum Therapeutics, Inc.$4.3MNew
CMPS$CMPSCOMPASS Pathways plcadr$4.2MNew
DFTX$DFTXDefinium Therapeutics, Inc.$4.0MNew

What changed in Q2 2026

Against the previous quarter's 13F: 23 new, 11 added to, 7 trimmed, 17 sold out. Share-count changes; largest moves by dollar size first.

New positions (23)

  • ELVN$ELVNEnliven Therapeutics, Inc.$8.1M

    first bought this quarter

  • BIOA$BIOACALLBioAge Labs, Inc.$6.1M

    first bought this quarter

  • ADAG$ADAGAdagene Inc.$5.3M

    first bought this quarter

  • FBRX$FBRXForte Biosciences, Inc.$4.8M

    first bought this quarter

  • RZLT$RZLTCALLRezolute, Inc.$4.7M

    first bought this quarter

  • IFRX$IFRXInflaRx N.V.$4.5M

    first bought this quarter

+17 more in the Excel export

Added to (11)

  • CCCC$CCCCC4 Therapeutics, Inc.+220%

    now $33.6M · held 2 qtrs, 2 adds in a row

  • IVA$IVAInventiva S.A.+355%

    now $9.2M · held 3+ qtrs, 2 adds in a row

  • RLAY$RLAYRelay Therapeutics, Inc.+44%

    now $18.1M · held 2 qtrs, 2 adds in a row

  • KOD$KODKodiak Sciences Inc.+32%

    now $19.5M · held 3+ qtrs, 2 adds in a row

  • COGT$COGTCogent Biosciences, Inc.+10%

    now $33.5M · held 3+ qtrs

  • AVBP$AVBPCALLArriVent BioPharma, Inc.+66%

    now $6.4M

+5 more in the Excel export

Trimmed (7)

  • SCYX$SCYXSCYNEXIS INC-90%

    now $3.1M · held 2 qtrs

  • RLMD$RLMDRELMADA THERAPEUTICS, INC.-13%

    now $50.9M · held 3+ qtrs

  • ANL$ANLAdlai Nortye Group Ltd.-40%

    now $8.8M · held 2 qtrs

  • EWTX$EWTXEdgewise Therapeutics, Inc.-17%

    now $11.8M · held 3+ qtrs

  • IKT$IKTInhibikase Therapeutics, Inc.-14%

    now $6.1M · held 3+ qtrs, 2 trims in a row

  • KTTA$KTTAPasithea Therapeutics Corp.-52%

    now $515K · held 3+ qtrs

+1 more in the Excel export

Sold out (17)

  • KALV$KALVKalVista Pharmaceuticals, Inc.was $19.8M

    held 2+ qtrs

  • ABVX$ABVXAbivax S.A.was $14.5M

    held 2+ qtrs

  • NKTR$NKTRNEKTAR THERAPEUTICSwas $9.0M

    held 1 qtr

  • KALV$KALVCALLKalVista Pharmaceuticals, Inc.was $6.3M
  • EPRX$EPRXEUPRAXIA PHARMACEUTICALS INC.was $4.9M

    held 2+ qtrs

  • GHRS$GHRSGH Research PLCwas $4.6M

+11 more in the Excel export

Firm AUM (Form ADV): $385.7M as of 2025-12-31 · SEC IAPD

Share

Holdings by quarter

Every 13F Squadron Capital Management LLC has filed, 2 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow Squadron Capital Management?

Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 26, 2026.

Average quality of Squadron Capital Management's top 20 holdings: 25/100 (our AI quality score, weighted by position size; 5 of the 20 are scored)

Top 10 since filing

-10.7%

Value-weighted move of the 10 largest stock positions

Turnover

30%

Last quarter

Top 10 weight

73%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

0%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 8 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q4 2025 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

Squadron Capital Management LLC disclosed 43 positions worth $322.2M in its Form 13F-HR for Q2 2026 — $292.1M in common stock plus $30.2M of put/call option positions (reported at underlying notional value, not premium at risk), led by $RLMD (RELMADA THERAPEUTICS, INC.) at 17.4% of the equity portfolio, followed by $CCCC and $COGT. During the quarter the fund opened 23 new positions and exited 17 — including a new stake in $ELVN and a full exit from $KALV. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Squadron Capital Management LLC’s Form 13F-HR filing with the SEC under CIK 2050709.

Funds like this

managers whose biggest positions overlap Squadron Capital Management's
Commodore Capital LP$1.68B 13F book · 8 shared top holdingsCOGTRLAYELVNASMBOctagon Capital Advisors LP$1.11B 13F book · 7 shared top holdingsCOGTBIOAAVBPPALIIkarian Capital, LLC$928.17M 13F book · 9 shared top holdingsKODRLMDCOGTCCCCSpruce Street Capital LP$509.68M 13F book · 5 shared top holdingsRLMDRLAYELVNIKTFairmount Funds Management LLC$1.51B 13F book · 3 shared top holdingsCOGTELVNIKTSILVERARC CAPITAL MANAGEMENT, LLC$962.15M 13F book · 6 shared top holdingsCOGTELVNKODCCCC

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: Squadron Capital Management LLC

13F Pro is an AI hedge fund tracker and stock research platform. For Squadron Capital Management LLC (SEC CIK: 2050709), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in Squadron Capital Management LLC's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.